Summary
Congenital disorders of glycosylation (CDG) are a group of over 100 inherited disorders characterised by defective glycosylation of proteins and lipids. Although the phenotypic and genetic characteristics of CDG as a whole are well established, their pathophysiology is poorly understood. In addition, the phenotype of affected patients is extremely variable, with dramatically different clinical presentations often appearing in patients with mutations in the same gene. I plan to investigate the link between pathogenic mutation and phenotype using recent advances in omics technologies, with a focus on the regulation of genes implicated in the pathophysiology of CDG.
Firstly, using transcriptomics and epigenomics, I will identify the mechanism by which mutations in homologous genes encoding subunits of the oligosaccharyltransferase (OST) complex cause divergent phenotypes, thought to be due to differences in the regulation of tissue-specific transcription. The primary model for these studies will be the MAGT1 gene, mutations in which can lead to either a severe developmental disorder (MAGT1-CDG) or an isolated primary immune deficiency (XMEN). Secondly, using glycoproteomic techniques, I will study the proteins most affected by aberrant glycosylation in CDG affecting the OST, thereby characterising their pathophysiology in both patient-derived and modified cell lines. findings will be further investigated using targeted techniques such as LC-MS/MS. In summary, this study will simultaneously provide valuable insight into both the pathophysiology of CDG and the functional regulation of the OST complex, an understudied aspect of cell biology.
Firstly, using transcriptomics and epigenomics, I will identify the mechanism by which mutations in homologous genes encoding subunits of the oligosaccharyltransferase (OST) complex cause divergent phenotypes, thought to be due to differences in the regulation of tissue-specific transcription. The primary model for these studies will be the MAGT1 gene, mutations in which can lead to either a severe developmental disorder (MAGT1-CDG) or an isolated primary immune deficiency (XMEN). Secondly, using glycoproteomic techniques, I will study the proteins most affected by aberrant glycosylation in CDG affecting the OST, thereby characterising their pathophysiology in both patient-derived and modified cell lines. findings will be further investigated using targeted techniques such as LC-MS/MS. In summary, this study will simultaneously provide valuable insight into both the pathophysiology of CDG and the functional regulation of the OST complex, an understudied aspect of cell biology.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/894669 |
| Start date: | 01-07-2020 |
| End date: | 30-06-2022 |
| Total budget - Public funding: | 178 320,00 Euro - 178 320,00 Euro |
Cordis data
Original description
Congenital disorders of glycosylation (CDG) are a group of over 100 inherited disorders characterised by defective glycosylation of proteins and lipids. Although the phenotypic and genetic characteristics of CDG as a whole are well established, their pathophysiology is poorly understood. In addition, the phenotype of affected patients is extremely variable, with dramatically different clinical presentations often appearing in patients with mutations in the same gene. I plan to investigate the link between pathogenic mutation and phenotype using recent advances in omics technologies, with a focus on the regulation of genes implicated in the pathophysiology of CDG.Firstly, using transcriptomics and epigenomics, I will identify the mechanism by which mutations in homologous genes encoding subunits of the oligosaccharyltransferase (OST) complex cause divergent phenotypes, thought to be due to differences in the regulation of tissue-specific transcription. The primary model for these studies will be the MAGT1 gene, mutations in which can lead to either a severe developmental disorder (MAGT1-CDG) or an isolated primary immune deficiency (XMEN). Secondly, using glycoproteomic techniques, I will study the proteins most affected by aberrant glycosylation in CDG affecting the OST, thereby characterising their pathophysiology in both patient-derived and modified cell lines. findings will be further investigated using targeted techniques such as LC-MS/MS. In summary, this study will simultaneously provide valuable insight into both the pathophysiology of CDG and the functional regulation of the OST complex, an understudied aspect of cell biology.
Status
CLOSEDCall topic
MSCA-IF-2019Update Date
28-04-2024
Images
No images available.
Geographical location(s)
